A comprehensive insight on ocular pharmacokinetics

被引:338
作者
Agrahari, Vibhuti [1 ]
Mandal, Abhirup [1 ]
Agrahari, Vivek [1 ,2 ]
Trinh, Hoang M. [1 ]
Joseph, Mary [1 ]
Ray, Animikh [1 ]
Hadji, Hicheme [3 ]
Mitra, Ranjana [1 ]
Pal, Dhananjay [1 ]
Mitra, Ashim K. [1 ]
机构
[1] Univ Missouri Kansas City, Sch Pharm, Div Pharmaceut Sci, 2464 Charlotte St, Kansas City, MO 64108 USA
[2] Bayer HealthCare LLC, Shawnee, KS 66216 USA
[3] Univ Algiers, Fac Pharm, Algiers, Algeria
关键词
Ocular pharmacokinetics; Compartment models; Animal models; Simulation study; Anterior chamber; Posterior chamber; Transporter; MONOESTER GANCICLOVIR PRODRUGS; AMINO-ACID TRANSPORTER; DRUG-DELIVERY; RABBIT CORNEA; P-GLYCOPROTEIN; OLIGOPEPTIDE TRANSPORTER; MACULAR DEGENERATION; ANTERIOR-CHAMBER; MEDIATED EFFLUX; APTAMER NX1838;
D O I
10.1007/s13346-016-0339-2
中图分类号
TH7 [仪器、仪表];
学科分类号
080401 [精密仪器及机械];
摘要
The eye is a distinctive organ with protective anatomy and physiology. Several pharmacokinetics compartment models of ocular drug delivery have been developed for describing the absorption, distribution, and elimination of ocular drugs in the eye. Determining pharmacokinetics parameters in ocular tissues is a major challenge because of the complex anatomy and dynamic physiological barrier of the eye. In this review, pharmacokinetics of these compartments exploring different drugs, delivery systems, and routes of administration is discussed including factors affecting intraocular bioavailability. Factors such as precorneal fluid drainage, drug binding to tear proteins, systemic drug absorption, corneal factors, melanin binding, and drug metabolism render ocular delivery challenging and are elaborated in this manuscript. Several compartment models are discussed; these are developed in ocular drug delivery to study the pharmacokinetics parameters. There are several transporters present in both anterior and posterior segments of the eye which play a significant role in ocular pharmacokinetics and are summarized briefly. Moreover, several ocular pharmacokinetics animal models and relevant studies are reviewed and discussed in addition to the pharmacokinetics of various ocular formulations.
引用
收藏
页码:735 / 754
页数:20
相关论文
共 95 条
[1]
Recent advances in ocular drug delivery [J].
Achouri, Djamila ;
Alhanout, Kamel ;
Piccerelle, Philippe ;
Andrieu, Veronique .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (11) :1599-1617
[2]
Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation [J].
Akpek, Esen Karamursel ;
Vittitow, Jason ;
Verhoeven, Rozemarijn S. ;
Brubaker, Kurt ;
Amar, Thierry ;
Powell, Kendall D. ;
Boyer, Jose L. ;
Crean, Christopher .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 25 (05) :433-439
[3]
In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations [J].
Almeida, Hugo ;
Amaral, Maria Helena ;
Lobao, Paulo ;
Sousa Lobo, Jose Manuel .
DRUG DISCOVERY TODAY, 2014, 19 (04) :400-412
[4]
Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits [J].
Amar, Thierry ;
Caillaud, Thierry ;
Elena, Pierre-Paul .
CURRENT EYE RESEARCH, 2008, 33 (02) :149-158
[5]
Loteprednol etabonate ophthalmic suspension 0.5 %: Efficacy and safety for postoperative anti-inflammatory use [J].
Amon M. ;
Busin M. .
International Ophthalmology, 2012, 32 (5) :507-517
[6]
Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea [J].
Anand, BS ;
Mitra, AK .
PHARMACEUTICAL RESEARCH, 2002, 19 (08) :1194-1202
[7]
Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: Interactions with the neutral and cationic amino acid transporter on the corneal epithelium [J].
Anand, BS ;
Katragadda, S ;
Nashed, YE ;
Mitra, AK .
CURRENT EYE RESEARCH, 2004, 29 (2-3) :153-166
[8]
Current prodrug strategies via membrane transporters/receptors [J].
Anand, BS ;
Dey, S ;
Mitra, AK .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (06) :607-620
[9]
Anecortave acetate in the treatment of age-related macular degeneration [J].
Augustin, Albert .
CLINICAL INTERVENTIONS IN AGING, 2006, 1 (03) :237-246
[10]
The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development [J].
Awwad, Sahar ;
Lockwood, Alastair ;
Brocchini, Steve ;
Khaw, Peng T. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (10) :3330-3342